## OROGEN

## Orogen Royalties Announces Results of the 2023 Annual General and Special Meeting

Vancouver, B.C. October 26, 2023 (TSX.V:OGN) (OTCQX:OGNRF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce the voting results for its Annual General and Special Meeting (the "Meeting") of shareholders held October 25, 2023.

A total of 55,155,897 shares were voted by proxy representing 28.52% of the issued and outstanding shares of the Company. Shareholders approved all matters presented at the Meeting as follows:

Director Nominee	Votes	Votes	Withheld/	% For	% Against	%
	For	Against	Abstain			Withheld/
						Abstain
Number of Directors	55,142,474	13,423	ı	99.98	0.02	-
J. Patrick Nicol	52,762,552	ı	2,393,345	95.66	ı	4.34
Justin Quigley	55,144,341	ı	11,556	99.98	ı	0.02
Roland Butler	55,144,341		11,556	99.98	-	0.02
Samantha Shorter	55,137,495	-	18,402	99.97	-	0.03
Timothy Janke	55,144,327	-	11,570	99.98	-	0.02
Appointment of Auditor	55,125,607	-	30,290	99.95	-	0.05
Omnibus Equity Incentive	55,005,121	150,776	-	99.73	0.27	0.05
Compensation Plan						

Each of the resolutions approved at the Meeting are described in detail in the Company's Management Proxy Circular dated September 14, 2023, available on SEDAR+ at www.sedarplus.ca and the Company's website at www.orogenroyalties.com.

## **About Orogen Royalties Inc.**

Orogen Royalties is focused on organic royalty creation and royalty acquisitions on precious and base metal discoveries in western North America. The Company's royalty portfolio includes the producing Ermitaño gold and silver Mine in Sonora, Mexico (2.0% NSR royalty) operated by First Majestic Silver Corp. and the Silicon-Merlin gold project (1.0% NSR royalty) in Nevada, U.S.A, being advanced by AngloGold Ashanti. The Company is well financed with several projects actively being developed by joint venture partners.

On Behalf of the Board **OROGEN ROYALTIES INC.** 

Paddy Nicol President & CEO

To find out more about Orogen, please contact Paddy Nicol, President & CEO at 604-248-8648, and Marco LoCascio, Vice President of Corporate Development at 604-248-8648. Visit our website at <a href="https://www.orogenroyalties.com">www.orogenroyalties.com</a>.

Orogen Royalties Inc.

1015 – 789 West Pender Street

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Vancouver, BC Canada V6C 1H2 info@orogenroyalties.com

## **Forward Looking Information**

This news release includes certain statements that may be deemed "forward looking statements". All statements in this presentation, other than statements of historical facts, that address events or developments that Orogen Royalties Inc. (the "Company") expect to occur, are forward looking statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur.

Although the Company believe the expectations expressed in such forward looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward looking statements. Factors that could cause the actual results to differ materially from those in forward looking statements include market prices, exploitation and exploration successes, and continued availability of capital and financing, and general economic, market or business conditions. Furthermore, the extent to which COVID-19 may impact the Company's business will depend on future developments such as the geographic spread of the disease, the duration of the outbreak, travel restrictions, physical distancing, business closures or business disruptions, and the effectiveness of actions taken in Canada and other countries to contain and treat the disease. Although it is not possible to reliably estimate the length or severity of these developments and their financial impact as of the date of approval of these condensed interim consolidated financial statements, continuation of the prevailing conditions could have a significant adverse impact on the Company's financial position and results of operations for future periods.

Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward looking statements. Forward looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by securities laws, the Company undertakes no obligation to update these forward looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.